Shell Asset Management’s Kyntra Bio KYNB Stock Holding History

Shell Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-285	Closed	-$264K	–	1459
2020 Q4	$264K	Hold	285	–	–	0.01%	1044
2020 Q3	$293K	Hold	285	–	–	0.01%	911
2020 Q2	$288K	Sell	285 -2	-0.7%	-$1.86K	0.01%	908
2020 Q1	$250K	Sell	287 -5	-2%	-$4.97K	0.01%	937
2019 Q4	$313K	Sell	292 -6	-2%	-$6.13K	0.01%	1045
2019 Q3	$275K	Sell	298 -2	-0.7%	-$2.2K	0.01%	1075
2019 Q2	$339K	Sell	300 -7	-2%	-$7.66K	0.01%	1038
2019 Q1	$418K	Hold	307	–	–	0.01%	980
2018 Q4	$356K	Sell	307 -28	-8%	-$31.5K	0.01%	946
2018 Q3	$509K	Hold	335	–	–	0.01%	954
2018 Q2	$525K	Sell	335 -18	-5%	-$23.5K	0.01%	924
2018 Q1	$408K	Hold	353	–	–	0.01%	963
2017 Q4	$419K	Buy	+353	New	+$443K	0.01%	952

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Shell Asset Management's KYNB Position: Q1 2021 in Review

Shell Asset Management sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 285 shares — an estimated $264K sold.

Shell Asset Management first reported a position in KYNB in Q4 2017 and held it in 13 quarters. The position peaked at $525K in Q2 2018. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

Shell Asset Management reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
Shell Asset Management sold 285 Kyntra Bio shares in Q1 2021, an estimated $264K.
Shell Asset Management first reported a position in Kyntra Bio in Q4 2017 and held it in 13 quarters.
Shell Asset Management's Kyntra Bio position peaked at $525K in Q2 2018.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.